Physician profile

Nathan Eric Beneze

Family Medicine · Bullhead City, AZ

NPI 1346286325

$408.63

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$132.59
Education$61.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Nevro Corp. $109.95 2021
Pfizer INC. $85.90 2021-2024
Astellas Pharma US INC $82.57 2020-2023
Amgen INC. $35.06 2023-2024 Repatha, Otezla
Abbvie INC. $31.74 2023 Ubrelvy, Qulipta
Glaxosmithkline, LLC. $17.30 2020
Esperion Therapeutics, INC. $16.32 2021
Merck Sharp & Dohme LLC $16.03 2020
Tactile Systems Technology INC $13.76 2023 Entre Plus, Flexitouch Plus

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Nathan Eric Beneze

$408.63

in general payments reported 2019-2025

Years
2020-2024
Top company
Nevro Corp.

https://glasscript.com/doctor/16022/nathan-eric-beneze

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.